Xilio Therapeutics, Inc. Notes Payable, Current
Xilio Therapeutics, Inc. (XLO) had Notes Payable, Current of $3.31 million as of 2023-12-31, per its 10-K filed 2025-03-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Long-Term Debt and Lease Obligation, Current
us-gaap:NotesPayableCurrent · last filed 2025-03-11
- 2023-12-31: Notes Payable, Current $3.31M.
- 2023-09-30: Notes Payable, Current $4.96M.
- 2023-06-30: Notes Payable, Current $7.14M.
- 2023-03-31: Notes Payable, Current $6.67M.
| Period end | Notes Payable, Current |
|---|---|
| 2023-12-31 | $3.31M 10-K · filed 2025-03-11 |
| 2023-09-30 | $4.96M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $7.14M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $6.67M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $6.67M 10-K · filed 2024-04-01 |
| 2022-09-30 | $5.00M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $3.33M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $1.67M 10-Q · filed 2022-05-12 |
| 2020-12-31 | $2.33M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |